Semalytix
Founded 2015 · 43 employees on LinkedIn · 2 known investors
Semalytix builds Project Atlas, an agentic AI platform that converts multilingual patient experience data into continuous intelligence for pharmaceutical medical, commercial, HEOR and pharmacovigilance teams. It monitors patient voice across 26 languages and 144 countries, offering modules for pharmacovigilance, respiratory-outbreak detection, and treatment adherence.
Also known as Semalytix GmbH
Investors · 2
Company profile
researched Aug 2026Semalytix is a company focused on analysing Patient Experience Data for the pharmaceutical industry. Its core product, Project Atlas, is described as an agentic AI platform that converts the global, multilingual patient voice into a continuous intelligence stream for medical, commercial and safety functions. Atlas monitors patient discourse across 26 languages and 144 countries on a daily basis and is positioned as being built on more than ten years of supervised AI work dedicated to the patient voice.
The platform is organised around a continuous-monitoring model rather than periodic research cycles, and can be configured against a specific brand, asset or therapeutic-area objective so that the same patient corpus can be queried differently by different internal teams. Three agent modules, referred to as Sentinels, run on Atlas: Safety Sentinel for pharmacovigilance signal detection from public digital discourse, engineered so that no individual case constitutes a valid ICSR at the point of marketing-authorisation-holder access; Outbreak Sentinel, a respiratory-outbreak radar for influenza-like illness, COVID-19 and RSV signals stated to appear one to six weeks ahead of traditional surveillance; and Adherence Sentinel, which is said to detect patients discontinuing treatment six to ten weeks before refill gaps appear in claims data.
Business model
Semalytix provides a software platform, Project Atlas, together with agent modules (Safety, Outbreak and Adherence Sentinels) to pharmaceutical enterprise teams.
▸Full profile — market position, technology, go-to-market, geography
Market position
Semalytix positions itself in the patient experience data and patient-voice analytics segment serving pharmaceutical enterprises, citing use by top-10 pharma companies and more than ten years of dedicated work on supervised AI for the patient voice.
The company emphasises continuous, always-on monitoring between formal review cycles instead of periodic research projects; traceability of every signal to a verified patient utterance with no synthetic data; objective-aware configuration so the same corpus serves different team questions; and an enterprise compliance posture with supervised guardrails and full provenance intended to shorten data-protection review timelines.
Technology
Project Atlas is an agentic AI platform built on supervised machine learning applied to patient-generated content. It ingests multilingual patient utterances across 26 languages and 144 countries and processes them into structured signals, with each signal traceable to a verified patient utterance rather than synthetic data. The architecture is described as compliance-first, incorporating supervised guardrails and full data provenance, and configurable so that analysis is oriented toward a stated brand, asset or therapeutic-area objective. Agent modules layered on the platform cover pharmacovigilance, respiratory-outbreak detection and treatment adherence.
Go-to-market
Pharmaceutical companies, including top-10 pharma organisations, with usage spanning Medical Affairs, Commercial, health economics and outcomes research (HEOR), and Pharmacovigilance teams. Data protection officers at large pharmaceutical firms are cited as stakeholders in platform approval.
Geography
Patient voice monitoring spans 144 countries and 26 languages.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 1
primary sources listed
- Semalytixsemalytix.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Semalytix do?
- Semalytix builds Project Atlas, an agentic AI platform that turns multilingual patient voice data into intelligence for pharma.
- Who are Semalytix's investors?
- Semalytix's investors include Fly Ventures, Matterwave Ventures.